NCT06340360 A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT06136741 A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05664217 NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma Status TERMINATED Phase PHASE2/PHASE3
NCT05632809 REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE) Status RECRUITING Phase PHASE2
NCT05359211 NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT04969861 BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) Status TERMINATED Phase PHASE2/PHASE3
NCT04955262 A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab Status WITHDRAWN Phase PHASE1
NCT04936841 Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma Status TERMINATED Phase PHASE2
NCT04730349 A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer Status TERMINATED Phase PHASE1/PHASE2
NCT04677179 A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) Status TERMINATED Phase PHASE2
NCT04646044 A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19 Status COMPLETED Phase PHASE1
NCT04616196 Study of NKTR 255 in Combination With Cetuximab in Solid Tumors Status COMPLETED Phase PHASE1/PHASE2
NCT04540705 A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread Status COMPLETED Phase PHASE1
NCT04433585 A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE) Status COMPLETED Phase PHASE2
NCT04410445 Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence Status TERMINATED Phase PHASE3
NCT04209114 A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer Status COMPLETED Phase PHASE3